Characterization of Glycosylation in Protein Drugs

Characterization of Glycosylation in Protein Drugs

Most biotherapeutic products are glycoproteins, including glycosyltransferases, glycosidases, erythropoietin, and cytokines. The drugs themselves are complex, but to better assess their effects, there is an urgent need to develop methods to characterize glycosylation. CD BioGlyco is a leader in glycosylation characterization. We have developed a comprehensive Glycoproteomics Platform to provide customers with the characterization of glycosylation in protein drugs. Welcome customers from all over the world to cooperate with us!

Glycosylation of Protein Drugs

Approved therapeutic protein drugs have grown exponentially over the past few decades. These drugs are used in cancer, diabetes, neutropenia, rheumatoid arthritis, et al. This solidified the position of biologics in the drug market. Glycosylation is one of the most important post-translational modifications during protein characterization. As a key quality attribute of therapeutic protein drugs, it affects the biological activity, serum half-life, stability, and immunogenicity of the drug, changing the way the drug interacts with the patient's cells. Therefore, quantitative analytical methods are needed to accurately characterize glycosylation in biopharmaceutical processes.

Characterization of Glycosylation in Protein Drugs

Analytical Methods of Glycosylation

The glycan portion of therapeutic proteins has been reported to significantly affect their pharmacodynamics and pharmacokinetics, as well as effects on protein folding, targeting, transport, ligand binding, and more. Therefore, scientists usually characterize glycans by high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), liquid chromatography-MS (LC-MS), capillary electrophoresis (CE), matrix-assisted laser desorption/ionization-MS (MALDI/TOF-MS), etc. For example, fluorescent LC labeled with 1,2-diamino-4,5-methylenedioxybenzene (DMB) is used for the quantification and analysis of sialic acid.

Our Characterization Services

Based on the importance of glycosylation in protein drugs, CD BioGlyco provides customers with comprehensive characterization services of glycosylation in protein drugs. Our services include but are not limited to:

  • Identification and quantification of a variety of monosaccharides, including fucose, mannose, and galactose.
  • Identification and quantification of sialic acid, including N-acetylneuraminic acid and N-glycolneuraminic acid.
  • Overall analysis of oligosaccharides
    LC-MS and MALDI/TOF-MS are used to analyze N-glycans and O-glycans in protein drugs.
  • Glycosylation site analysis
    LC-MS detects hydrolyzed digests of specific proteins and then analyzes the glycans at each glycosylation site by collecting isolated glycopeptides.
  • Site occupancy analysis

CD BioGlyco is committed to research in the field of glycosylation for many years, providing our customers with high-quality, cost-effective, and hassle-free glycosylation characterization services. If you are interested in our services, please feel free to contact us, we are looking forward to being your indispensable assistant in glycosylation characterization.


  1. Krull, I.; et al. A review of recent developments in analytical characterization of glycosylation in therapeutic proteins. LCGC North America. 2020, 28(1): 30-37.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.